vs
EXACT SCIENCES CORP（EXAS）与KB HOME（KBH）财务数据对比。点击上方公司名可切换其他公司
KB HOME的季度营收约是EXACT SCIENCES CORP的1.9倍（$1.7B vs $878.4M），KB HOME净利率更高（6.0% vs -9.8%，领先15.8%），EXACT SCIENCES CORP同比增速更快（23.1% vs -15.3%），KB HOME自由现金流更多（$290.1M vs $120.4M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 7.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
KB Home是美国知名住宅建造企业，1957年于密歇根州底特律成立，前身为Kaufman & Broad，是首家在纽约证券交易所上市的住宅建造商，总部现位于加利福尼亚州洛杉矶。
EXAS vs KBH — 直观对比
营收规模更大
KBH
是对方的1.9倍
$878.4M
营收增速更快
EXAS
高出38.4%
-15.3%
净利率更高
KBH
高出15.8%
-9.8%
自由现金流更多
KBH
多$169.6M
$120.4M
两年增速更快
EXAS
近两年复合增速
7.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.7B |
| 净利润 | $-86.0M | $101.5M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | — |
| 净利率 | -9.8% | 6.0% |
| 营收同比 | 23.1% | -15.3% |
| 净利润同比 | 90.1% | -46.7% |
| 每股收益（稀释后） | $-0.45 | $1.55 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASKBH
| Q4 25 | $878.4M | $1.7B | ||
| Q3 25 | $850.7M | $1.6B | ||
| Q2 25 | $811.1M | $1.5B | ||
| Q1 25 | $706.8M | $1.4B | ||
| Q4 24 | $713.4M | $2.0B | ||
| Q3 24 | $708.7M | $1.8B | ||
| Q2 24 | $699.3M | $1.7B | ||
| Q1 24 | $637.5M | $1.5B |
净利润EXASKBH
| Q4 25 | $-86.0M | $101.5M | ||
| Q3 25 | $-19.6M | $109.8M | ||
| Q2 25 | $-1.2M | $107.9M | ||
| Q1 25 | $-101.2M | $109.6M | ||
| Q4 24 | $-864.6M | $190.6M | ||
| Q3 24 | $-38.2M | $157.3M | ||
| Q2 24 | $-15.8M | $168.4M | ||
| Q1 24 | $-110.2M | $138.7M |
毛利率EXASKBH
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASKBH
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | — | ||
| Q2 25 | -0.3% | — | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | -3.8% | — | ||
| Q1 24 | -16.7% | — |
净利率EXASKBH
| Q4 25 | -9.8% | 6.0% | ||
| Q3 25 | -2.3% | 6.8% | ||
| Q2 25 | -0.1% | 7.1% | ||
| Q1 25 | -14.3% | 7.9% | ||
| Q4 24 | -121.2% | 9.5% | ||
| Q3 24 | -5.4% | 9.0% | ||
| Q2 24 | -2.3% | 9.9% | ||
| Q1 24 | -17.3% | 9.4% |
每股收益（稀释后）EXASKBH
| Q4 25 | $-0.45 | $1.55 | ||
| Q3 25 | $-0.10 | $1.61 | ||
| Q2 25 | $-0.01 | $1.50 | ||
| Q1 25 | $-0.54 | $1.49 | ||
| Q4 24 | $-4.69 | $2.50 | ||
| Q3 24 | $-0.21 | $2.04 | ||
| Q2 24 | $-0.09 | $2.15 | ||
| Q1 24 | $-0.60 | $1.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $3.9B |
| 总资产 | $5.9B | $6.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASKBH
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — | ||
| Q1 24 | $652.1M | — |
股东权益EXASKBH
| Q4 25 | $2.4B | $3.9B | ||
| Q3 25 | $2.5B | $3.9B | ||
| Q2 25 | $2.5B | $4.0B | ||
| Q1 25 | $2.4B | $4.1B | ||
| Q4 24 | $2.4B | $4.1B | ||
| Q3 24 | $3.2B | $4.0B | ||
| Q2 24 | $3.2B | $4.0B | ||
| Q1 24 | $3.1B | $3.9B |
总资产EXASKBH
| Q4 25 | $5.9B | $6.7B | ||
| Q3 25 | $5.9B | $7.0B | ||
| Q2 25 | $5.8B | $7.0B | ||
| Q1 25 | $5.7B | $7.0B | ||
| Q4 24 | $5.9B | $6.9B | ||
| Q3 24 | $6.7B | $6.8B | ||
| Q2 24 | $6.7B | $6.8B | ||
| Q1 24 | $6.4B | $6.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $303.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $290.1M |
| 自由现金流率自由现金流/营收 | 13.7% | 17.1% |
| 资本支出强度资本支出/营收 | 3.6% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 2.99× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $287.3M |
8季度趋势，按日历期对齐
经营现金流EXASKBH
| Q4 25 | $151.7M | $303.8M | ||
| Q3 25 | $219.9M | $197.7M | ||
| Q2 25 | $89.0M | $168.4M | ||
| Q1 25 | $30.8M | $-334.3M | ||
| Q4 24 | $47.1M | $362.6M | ||
| Q3 24 | $138.7M | $-89.9M | ||
| Q2 24 | $107.1M | $61.5M | ||
| Q1 24 | $-82.3M | $28.5M |
自由现金流EXASKBH
| Q4 25 | $120.4M | $290.1M | ||
| Q3 25 | $190.0M | $185.8M | ||
| Q2 25 | $46.7M | $156.9M | ||
| Q1 25 | $-365.0K | $-345.5M | ||
| Q4 24 | $10.7M | $352.6M | ||
| Q3 24 | $112.6M | $-99.4M | ||
| Q2 24 | $71.2M | $51.2M | ||
| Q1 24 | $-120.0M | $19.1M |
自由现金流率EXASKBH
| Q4 25 | 13.7% | 17.1% | ||
| Q3 25 | 22.3% | 11.5% | ||
| Q2 25 | 5.8% | 10.3% | ||
| Q1 25 | -0.1% | -24.8% | ||
| Q4 24 | 1.5% | 17.6% | ||
| Q3 24 | 15.9% | -5.7% | ||
| Q2 24 | 10.2% | 3.0% | ||
| Q1 24 | -18.8% | 1.3% |
资本支出强度EXASKBH
| Q4 25 | 3.6% | 0.8% | ||
| Q3 25 | 3.5% | 0.7% | ||
| Q2 25 | 5.2% | 0.8% | ||
| Q1 25 | 4.4% | 0.8% | ||
| Q4 24 | 5.1% | 0.5% | ||
| Q3 24 | 3.7% | 0.5% | ||
| Q2 24 | 5.1% | 0.6% | ||
| Q1 24 | 5.9% | 0.6% |
现金转化率EXASKBH
| Q4 25 | — | 2.99× | ||
| Q3 25 | — | 1.80× | ||
| Q2 25 | — | 1.56× | ||
| Q1 25 | — | -3.05× | ||
| Q4 24 | — | 1.90× | ||
| Q3 24 | — | -0.57× | ||
| Q2 24 | — | 0.37× | ||
| Q1 24 | — | 0.21× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
KBH
| Home Building | $1.7B | 99% |
| Financial Service | $8.7M | 1% |
